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ABSTRACT
The clinical relevance of Campylobacter concisus in gastrointestinal disease has not been determined
deﬁnitively. This study investigated the phenotypic and genotypic characteristics of 39 C. concisus
isolates from Danish patients with diarrhoea, three isolates from healthy individuals and the type strain.
A cytolethal distending toxin (CDT)-like effect on Vero cells was observed in 35 (90%) isolates from
patients with diarrhoea, in all three isolates from healthy individuals and in the type strain. Analysis of
SDS-PAGE protein proﬁles and PCR ampliﬁcation of 23S rDNA assigned the isolates into two distinct,
but discordant groups. Automated ribotyping (RiboPrinting) identiﬁed 34 distinct patterns among the
43 isolates, but cluster analysis did not separate isolates from patients with diarrhoea from isolates from
healthy patients. Random ampliﬁed polymorphic DNA (RAPD) analysis with three primers identiﬁed
37 unique proﬁles, but requires further evaluation. The isolates obtained from healthy carriers were
distinguished by cluster analysis from the isolates obtained from patients with diarrhoea. All the isolates
were susceptible to 11 antimicrobial agents tested. Overall, there was considerable variability between
the C. concisus isolates, but there were no clear phenotypic or genotypic differences between isolates
from patients with diarrhoea and isolates from healthy carriers. Further evidence is needed to support
the possible role of C. concisus as a human enteric pathogen.
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INTRODUCTION
Campylobacter concisus, a fastidious and slow-
growing Gram-negative bacillus found in the
human oral cavity, was ﬁrst described in 1981
[1]. The species has been isolated in higher
proportions from relatively shallow and healthy
oral sites, suggesting that C. concisus is an oral
commensal rather than a clinically signiﬁcant oral
pathogen [2]. In addition, C. concisus can be
isolated from the faeces of patients with diarrhoea,
as well as from healthy individuals. Therefore, the
possible role of C. concisus as a gastrointestinal
pathogen has not yet been established ﬁrmly [3–7].
In contrast to the well-known human patho-
gens Campylobacter jejuni, Campylobacter coli,
Campylobacter lari and Campylobacter upsaliensis,
C. concisus has no known animal hosts, suggest-
ing that C. concisus is highly adapted to the
human gastrointestinal tract. Inter-personal
spread may be an important route of transmis-
sion, but is regarded as a relatively uncommon
phenomenon for thermophilic Campylobacter spp.
In a previous study, differences were observed
in the age distribution of C. concisus patients,
compared to the age distribution of patients
with C. jejuni ⁄C. coli infections [5]. Most isolates
were from the very young or elderly, indicating
that C. concisus is an opportunistic pathogen
for patients with immature or compromised
immune systems. C. concisus is a genotypically
heterogeneous species, and this may explain the
conﬂicting reports of its pathogenic potential.
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Multiple genomospecies within the species have
been described [6–11].
Several potential virulence factors have been
proposed for Campylobacter spp., including ﬂa-
gella-mediated motility, adhesion to intestinal
mucosa, invasion of the epithelial cells of the
intestine, and the ability to translocate and to
produce toxin. However, the speciﬁc virulence
mechanisms of Campylobacter spp. have not yet
been elucidated adequately [12]. The cytolethal
distending toxin (CDT) is the most characterised
of the Campylobacter toxins, and is encoded by the
three adjacent genes cdtA, cdtB and cdtC in
C. jejuni. The function of CDT in Campylobacter
pathogenesis is unknown, but it has been shown
that C. jejuni CDT causes sensitive cells to be
blocked in the G2 phase of their cell cycle.
The present study was conducted to determine
the phenotypic and genotypic heterogeneity,
and the pathogenic potential, of a collection of
C. concisus isolates.
MATERIALS AND METHODS
Bacterial strains
Thirty-nine C. concisus isolates from Danish patients with
diarrhoea, and three from healthy individuals, were studied.
All the C. concisus isolates were collected during a previous
study of the prevalence of campylobacters and related
organisms in faeces [5]. Five of the C. concisus-positive clinical
cases were coinfected with an established bacterial enteric
pathogen (three with Salmonella enterica subsp. enterica serovar
Enteritidis, one with Shigella sonnei, and one with Yersinia
enterocolitica). No patients or healthy individuals were related
epidemiologically. The C. concisus type strain CCUG 13144 was
included in all assays, and the identity of the clinical isolates
was reconﬁrmed by including the type strains of Campylobacter
mucosalis, C. upsaliensis and C. concisus on all protein proﬁling
gels. Growth conditions were as described below.
Phenotypic analysis
CDT-like activity by Vero cell assay
Bacterial cell-free supernatants and Vero cells were prepared
as described previously [13,14] with modiﬁcations [15].
Campylobacter cell-free ﬁltrate (50 lL) was added in duplicate
at the desired dilutions. A cell-free ﬁltrate from a Vero toxin-
producing Escherichia coli (VTEC strain H19, serotype
O26:H11) was used as a positive control, with Veal Infusion
Broth as a negative control. The controls were added in
duplicate to each plate in every assay. The CDT-like effect
was monitored daily for 3–6 days by phase-contrast micro-
scopy. The CDT-like titre of the supernatants was determined
by performing two-fold serial dilutions in a 96-well micro-
titration plate. The titre of a given assay was expressed as the
reciprocal of the highest dilution that caused at least 30% of
the cells in a well to be rounded or distended. Toxin
production by each C. concisus isolate was tested in at least
three independent assays with culture supernatants prepared
at different times.
Antimicrobial susceptibility testing
MICs were determined by the agar dilution method on
Mueller–Hinton-II agar supplemented with bovine blood 5%
v ⁄v [16]. Plates were incubated for 48 h at 37C in a
microaerobic atmosphere (O2 6%, CO2 7%, H2 7%, N2 80%,
v ⁄v). The MIC was deﬁned as the lowest concentration that
produced no visible growth. The dilution ranges (mg ⁄L) and
antimicrobial agents (Sigma Chemical Company, St Louis,
MO, USA) tested were as follows: erythromycin and tetra-
cycline, 0.25–32; nalidixic acid and streptomycin, 1–128;
ciproﬂoxacin, 0.03–16; gentamicin, 0.5–32; colistin and chlo-
ramphenicol, 0.5–64; sulphamethizole, 8–512; neomycin, 1–64;
and ampicillin 1–32.
Whole-cell protein proﬁling
This was performed as described previously [6], with the
modiﬁcation that C. concisus was harvested from blood agar
5% v ⁄v plates containing yeast extract 1% w ⁄v (SSI Diagnos-
tica, Hillerød, Denmark).
Molecular analysis
PCR ampliﬁcation of 23S rDNA
This was performed by the method of Bastyns et al. [17] with
modiﬁcations [11]. The method was modiﬁed by using the two
reverse primers (CON1 and CON2) independently, rather than
as a mixture, and was used to group the isolates. Sequences of
23S rDNA were ampliﬁed using the following primer pairs:
mixture A, forward primer MUC1 (5¢-ATGAGTAGCGAT-
AATTGGG-3¢) and reverse primer CON1 (5¢-CAGTATCGG-
CAATTCGCT-3¢); mixture B, forward primer MUC1 and
reverse primer CON2 (5¢-GACAGTATCAAGGATTTACG-3¢).
The sequences of the two reverse primers, CON1 and CON2,
are signiﬁcantly different, but yield a similar-sized PCR
fragment (306 bp). Isolates were grouped according to their
PCR product with either of the reverse primer sets A or B.
Automated ribotyping
This was performed using a RiboPrinter (DuPont Qualicon,
Wilmington, DE, USA), as described previously [18], with the
modiﬁcation that PvuII was used instead of HaeIII. The
riboprint proﬁles were aligned according to the position of a
molecular size standard on the RiboPrinter and were then
exported to a BioNumerics database (Applied Maths, Sint-
Martens-Latem, Belgium), and bands were assigned to the
proﬁles. These were compared with the Dice coefﬁcient
(position tolerance 1.0%, optimisation 0.5%), and a clustering
dendrogram was produced by the unweighted pair-group
method with arithmetic averages (UPGMA). Any discernible
difference (i.e., a change of band positions and ⁄or the loss or
gain of one or more bands) between patterns was considered
signiﬁcant when assessing inter-strain relationships.
Random ampliﬁed polymorphic DNA (RAPD) analysis
In brief, RAPD analysis was performed with Ready-To-Go
RAPD Analysis Beads (Pharmacia Biotech, Freiburg,
Germany), containing pre-mixed, pre-dispensed AmpliTaq
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DNA polymerase, as well as all necessary buffer ingredients
and nucleotides. Template DNA extraction procedures and
cycling parameters were as described previously [18]. The type
strain CCUG 13144 was included in each batch of assays as a
positive ampliﬁcation control, and all the isolates were tested
in two independent experiments on separate days to ensure
the reproducibility of the results. Fluorescently labelled prim-
ers 1281, 1254 and HLWL85 were used in three independent
ampliﬁcations, and the resultant PCR products were detected
on an ABI PRISM 310 (Applied Biosystems, Allerød,
Denmark). Proﬁles were analysed with BioNumerics software
using Pearson’s product-moment similarity coefﬁcient and
UPGMA clustering to determine proﬁle relatedness. The isolates
were grouped according to combined proﬁles based on each of
the three primers, with a cut-off level of 70% similarity.
RESULTS
CDT-like activity and antimicrobial
susceptibility
A CDT-like effect on Vero cells was detected in 35
(90%) of 39 isolates from patients with diarrhoea,
in all three (100%) isolates from healthy individ-
uals, as well as in the C. concisus type strain.
Repeat tests with a given supernatant were fully
reproducible, and in at least three independent
assays, toxin production by each isolate did not
vary by more than one dilution step. Six (14%)
isolates, including one from a healthy individual
and the type strain, produced high (1:64) CDT-
like titres, whereas 11 (25.6%) isolates, including
one from a healthy individual, produced a low
(1:8) CDT-like titre. The remaining 26 (60.4%)
isolates expressed intermediate CDT-like titres of
1:16 and 1:32. All 43 isolates in this study were
susceptible to all 11 antimicrobial agents tested
(data not shown).
SDS-PAGE of proteins
The 43 isolates could be divided into two variants:
group 1, which contained the C. concisus type
strain CCUG 13144 (of oral origin) and ﬁve
isolates from patients with diarrhoea; and group
2, which differed from group 1 by having addi-
tional bands at 200 kDa and 31 kDa. All three
isolates from healthy individuals belonged to
group 2. Considerable heterogeneity was found
in the lower regions of the gels.
PCR ampliﬁcation of 23S rDNA
By using primer combinations of either MUC1-
CON1 or MUC-CON2, the isolates could be
assigned into two distinct genotypes, with 14
(33.3%) of the 42 clinical isolates in genotype 1,
and 28 (66.7%) isolates in genotype 2. Of the three
isolates from healthy individuals, two were
assigned to genotype 1, and one to genotype 2.
Automated ribotyping
RiboPrinting differentiated the 43 isolates into 34
distinct patterns (RiboGroups). Seven Ribo-
Groups each contained two isolates, and one
RiboGroup contained three isolates. One isolate
(no. 1091) from a healthy individual was in the
same RiboGroup as an isolate from a patient with
gastroenteritis (Fig. 1). The type strain, originally
isolated from the oral cavity of a patient with
periodontal disease, belonged to the same Ribo-
Group as a gastroenteritis-related isolate. The
remaining two isolates from healthy carriers (6118
and 10375) had unique riboprints and showed
less relatedness to the major cluster (Fig. 1).
RAPD typing
Analysis of combined RAPD-DNA proﬁles,
based on each of the three primers, identiﬁed
37 unique reproducible proﬁles. Six isolates were
not tested with this method. The two tested
isolates (6118 and 1091) from healthy carriers
clustered separately from the isolates obtained
from patients with diarrhoea and from the type
strain (Fig. 2).
DISCUSSION
The deﬁnitive identiﬁcation of non-oral strains of
C. concisus, isolated from a number of different
sites throughout the human gastrointestinal tract,
including faeces, was described in 1989 [8].
However, knowledge is still limited regarding
the clinical importance of C. concisus, the occur-
rence of virulence factors, and genetic diversity.
This may be because the isolation techniques used
currently in many diagnostic laboratories may not
support the growth of C. concisus and other
potentially pathogenic non-jejuni ⁄ coli Campylo-
bacter spp. These organisms may be fastidious,
requiring an H2-enhanced microaerobic atmo-
sphere, special temperature conditions and pro-
longed incubation, or may be unable to tolerate
the antimicrobial agents included commonly in
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selective media [19–22]. Furthermore, correct
identiﬁcation may require additional advanced
techniques [5,23–26]. Therefore, isolation of this
species may be restricted to clinical microbiology
laboratories with special interests in C. concisus, as
this species, at present, is not an established
intestinal pathogen.
The present study detected a CDT-like effect on
Vero cells in 35 (90%) of 39 isolates from patients
with diarrhoea, and in all three isolates from
healthy individuals. The isolates from healthy
individuals differed from each other with respect
to toxin activity, but this activity was comparable
to that observed among gastroenteritis-associated
isolates. The type strain, isolated originally from
the oral cavity of a patient with periodontal
disease, also showed high CDT-like activity,
suggesting that this marker is not adequate for
identifying potential gastroenteric pathotypes of
C. concisus.
In C. jejuni, CDT is the most characterised of the
putative Campylobacter toxins. All human isolates
of C. jejuni seem to contain the cdt gene locus,
although differences in expression of the cdt gene
exist [27,28]. It has been shown that C. jejuni CDT
causes progressive cellular distension, and ulti-
mately death, in Chinese hamster ovary (CHO),
Vero, Hep-2 and HeLa cells [29]. The cdt genes in
C. jejuni have been cloned and sequenced [30],
and the cdtA, cdtB and cdtC genes encode proteins
with predicted molecular sizes of 30.1, 29.0 and
21.1 kDa, respectively. The function of CDT pro-
teins in Campylobacter pathogenesis is unknown,
although it has been shown that C. jejuni CDT
causes sensitive cells to be blocked in the G2
phase of their cell cycle, indicating that the CDT
has a mechanism of action different from that of
other bacterial toxins [31,32]. A direct causal role
of CDT in campylobacteriosis remains to be
demonstrated, although a signiﬁcant relationship
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Fig. 1. RiboGroup patterns of 43
isolates ordered according to their
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(UPGMA) clustering. The Dice simi-
larity coefﬁcient was used. The three
isolates from healthy carriers are
underlined. The scale refers to the
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between C. jejuni in-vitro toxigenicity (to Hep-2
and Vero cells) and the development of post-
infectious irritable bowel syndrome has been
reported [12,33]. Whether the CDT-like activity
observed in the present study is a result of the
expression of C. concicus cdt genes remains to be
proved following cloning of the C. concisus cdt
genes. However, Vero cells treated with cell-free
supernatants of the C. concisus isolates were
enlarged markedly (c. 2–5-fold) in comparison
with control cells (results not shown), which is a
common phenomenon observed with Vero cells
treated with the supernatant of C. jejuni CDT-
producing strains, as well as the supernatant from
other CDT-producing bacteria.
Virulence factors of C. concisus have only been
investigated in a few studies [11,34–36]. Russell
et al. [34] found that ten clinical C. concisus isolates
adhered to and invaded Hep-2 cells more efﬁ-
ciently than did C. jejuni and C. coli controls,
although only one strain each of C. jejuni and
C. coli were tested. Musmanno et al. [35] studied
two clinical isolates of C. concisus, both of which
failed to adhere to or invade cells, although one
isolate produced a cytotonic effect (elongation of
cells) on CHO cells, similar to that shown by
C. jejuni subsp. doylei, and induced intracytoplas-
matic vacuole formation similar to that caused by
cytotoxic Helicobacter pylori. Istivan et al. [11]
characterised a haemolytic phospholipase A2
activity in 19 clinical C. concisus isolates, all of
which produced vacuolating and cytolytic effects
on CHO cells in tissue culture and contained the
pldA gene, homologous to the pldA gene in C. coli.
An animal model, using BALB ⁄ cA mice pretreat-
ed with cyclophosphamide and intragastrically
challenged with C. concisus, showed transient
colonisation of the liver and ileum, and signs of
gastrointestinal disease, including weight loss
and loose stools. However, histological examina-
tion did not ﬁnd evidence of infection in colonised
organs, and the ﬁndings were not reproducible in
two later studies, possibly because of rapid
clearance of the organism [37].
All 43 isolates in the present study were fully
susceptible to all 11 antimicrobial agents tested,
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including erythromycin and nalidixic acid. Little
published information is available regarding the
antimicrobial susceptibility of this species. Greig
et al. [38] found that eight isolates from South
Africa were all sensitive to ciproﬂoxacin, tetra-
cycline, ampicillin and gentamicin, although
seven were resistant to erythromycin, while Van
Etterijck et al. [3] found that 51% of isolates from
Belgium were resistant to nalidixic acid. The drug
of choice for treatment of Campylobacter infections
is normally erythromycin or a ﬂuoroquinolone
[22], although increasing numbers of resistant
C. coli and C. jejuni isolates are now being
reported worldwide [39]. However, it seems that
resistance has not emerged in C. concisus, and the
present study suggests that erythromycin (or a
newer macrolide) should be considered if treat-
ment with antimicrobial agents is needed for
C. concisus infections.
C. concisus is considered to comprise at least two
genomospecies [8,9]. In the present study, SDS-
PAGE divided the 43 isolates into two broad
variants, containing 14% and 86% of the isolates,
respectively. The protein bands of lowermolecular
size were highly heterogeneous, indicating that
this size range may be used to further subdivide
the groups in future studies and increase the
discriminatory index of this typing method. The
prevalence of the two groups in the present study
was comparable to that found in a previous study
[6] of C. concisus isolates from Denmark, in which
the distribution of isolates in groups 1 and 2 was
15% (15 ⁄ 98) and 85% (82 ⁄ 98), respectively, and
patients infected with group 2 displayed more
signs of infection than patients infected with
group 1, although this latter observation was not
statistically signiﬁcant. Another Danish study [40]
evaluated 44 isolates from patients with diarrhoea
for their reactions with plant lectins. Although the
lectin typing system was both stable and repro-
ducible, no correlation between lectin reaction
pattern and patient category was observed.
The present study used PCR ampliﬁcation of
the 23S rDNA region to assign the isolates into
two deﬁnitive genotypes, genotype 1 (MUC1-
CON1) and genotype 2 (MUC1-CON2), compri-
sing 33.3% and 66.7% of the isolates, respectively.
In contrast, the relative frequencies of the same
genotypes among 21 Australian clinical isolates
and reference strains were 71.4% and 28.6%,
respectively [11] (T. S. Istivan, personal commu-
nication). DNA:DNA hybridisation experiments
[8] with a number of reference strains, including
CCUG 13144 (type strain) in the present study,
and CCUG 20034 in the study by Istivan et al. [11],
revealed that these two strains belonged to dif-
ferent DNA subgroups, in agreement with the
combined Australian and Danish results, which
also separated these two strains into two different
groups following repeated testing, thereby indi-
cating that a true difference in the geographical
distribution of these genotypes is the most
plausible explanation. Alignment of groups
obtained by 23S rDNA and SDS-PAGE analysis
in the present study showed remarkable disag-
reement in separation of strains, probably because
of the different typing targets analysed.
Ribotyping and RAPD typing have been used
to elucidate the complex epidemiology of ther-
mophilic Campylobacter spp. infections for out-
break investigations and surveillance purposes,
and to study disease associations [18,41–43].
RiboPrinting identiﬁed 34 RiboGroups among
the 43 isolates in the present study. Additional
RAPD-DNA analysis with three primers identi-
ﬁed unique proﬁles for all 37 isolates tested; six
isolates, including one from a healthy carrier,
were not tested by this method because of a
sudden loss of reproducibility, which is an inher-
ent problem of the technique and stresses the
importance of including a control strain in each
experiment. Only two isolates from healthy car-
riers were tested, and the ability of RAPD analysis
to discriminate between the two major popula-
tions needs further evaluation with more isolates
from healthy carriers. However, the substantial
heterogeneity observed among the C. concisus
isolates in this study supports previous ﬁndings
from Belgium and South African laboratories,
which have applied highly discriminatory geno-
typing techniques to study clinical isolates of
C. concisus [3,10]. Taken together, the molecular
epidemiological studies of C. concisus indicate that
the species consists of at least two genomospecies
with extensive genetic diversity. Studies of
C. jejuni have revealed diversity between isolates
at the phenotypic level for almost every charac-
teristic that has been implicated in pathogenicity.
However, this phenotypic variation does not
always coincide with observed or predicted dif-
ferences in virulence between clinical and non-
clinical isolates [12]. Clearly, further work is still
needed to determine whether C. concisus is a
signiﬁcant human enteric pathogen.
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